1425 related articles for article (PubMed ID: 23755989)
21. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.
Ajani JA; Mansfield PF; Crane CH; Wu TT; Lunagomez S; Lynch PM; Janjan N; Feig B; Faust J; Yao JC; Nivers R; Morris J; Pisters PW
J Clin Oncol; 2005 Feb; 23(6):1237-44. PubMed ID: 15718321
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A
Oncology; 2004; 67(1):48-53. PubMed ID: 15459495
[TBL] [Abstract][Full Text] [Related]
24. Benefit of neoadjuvant chemotherapy for Siewert type II esophagogastric junction adenocarcinoma.
Hosoda K; Yamashita K; Katada N; Moriya H; Mieno H; Sakuramoto S; Kikuchi S; Watanabe M
Anticancer Res; 2015 Jan; 35(1):419-25. PubMed ID: 25550582
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
[TBL] [Abstract][Full Text] [Related]
26. [Neoadjuvant chemotherapy for locally advanced gastric cancer].
Kalmár K; Cseke L; Káposztás Z; Horváth G; Varga E
Magy Seb; 2003 Oct; 56(5):177-84. PubMed ID: 15022621
[TBL] [Abstract][Full Text] [Related]
27. Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma.
Gaca JG; Petersen RP; Peterson BL; Harpole DH; D'Amico TA; Pappas TN; Seigler HF; Wolfe WG; Tyler DS
Ann Surg Oncol; 2006 Mar; 13(3):340-6. PubMed ID: 16485154
[TBL] [Abstract][Full Text] [Related]
28. A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
Larsen AC; Holländer C; Duval L; Schønnemann K; Achiam M; Pfeiffer P; Yilmaz MK; Thorlacius-Ussing O; Bæksgaard L; Ladekarl M
Ann Surg Oncol; 2015 May; 22(5):1540-7. PubMed ID: 25348777
[TBL] [Abstract][Full Text] [Related]
29. Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.
Spizzo G; Öfner D; de Vries A; Lukas P; Steger G; Pluschnig U; Zacherl J; Widder J; Zabernigg A; Gastl G; Mühlmann G
Ann Surg Oncol; 2011 Mar; 18(3):677-83. PubMed ID: 21063792
[TBL] [Abstract][Full Text] [Related]
30. Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
Jhawer M; Coit D; Brennan M; Qin LX; Gonen M; Klimstra D; Tang L; Kelsen DP; Shah MA
Am J Clin Oncol; 2009 Aug; 32(4):356-62. PubMed ID: 19381079
[TBL] [Abstract][Full Text] [Related]
31. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma.
Bekkar S; Gronnier C; Messager M; Robb WB; Piessen G; Mariette C;
Ann Thorac Surg; 2014 Jan; 97(1):303-10. PubMed ID: 24200394
[TBL] [Abstract][Full Text] [Related]
32. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
[TBL] [Abstract][Full Text] [Related]
33. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
[TBL] [Abstract][Full Text] [Related]
34. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
35. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Ychou M; Boige V; Pignon JP; Conroy T; Bouché O; Lebreton G; Ducourtieux M; Bedenne L; Fabre JM; Saint-Aubert B; Genève J; Lasser P; Rougier P
J Clin Oncol; 2011 May; 29(13):1715-21. PubMed ID: 21444866
[TBL] [Abstract][Full Text] [Related]
36. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study.
Ozdemir N; Abali H; Vural M; Yalcin S; Oksuzoglu B; Civelek B; Oguz D; Bostanci B; Yalcin B; Zengin N
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1139-47. PubMed ID: 25234436
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
[TBL] [Abstract][Full Text] [Related]
39. Treatment of locally advanced gastric cancer with the XELOX program of neoadjuvantchemotherapy combined with laparoscopic surgery: the experience in China.
Zheng CH; Lu J; Huang CM; Li P; Xie JW; Wang JB; Lin JX
Hepatogastroenterology; 2014 Oct; 61(135):1876-82. PubMed ID: 25713882
[TBL] [Abstract][Full Text] [Related]
40. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.
Fujitani K; Mano M; Hirao M; Kodama Y; Tsujinaka T
Ann Surg Oncol; 2012 Jun; 19(6):1936-43. PubMed ID: 22187120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
